Covid-19 immunisation drives should be prepared to deal with 'anti-vaxxers'
With the promising news around potential Covid-19 immunisation, it is wise not to ignore the rather successful anti-vaccination, or ‘anti-vaxx’, campaign that’s been underway as well, says Lekshmi Rita Venugopal, an epidemiologist and public health professional from the University of California, Berkeley.
Anti-vaccine activists have managed to use uncertainties surrounding the pandemic to propagate their agenda. Anti-lockdown demonstrations, claims of state interference in individual freedoms and conspiracy theories propagating anti-mask sentiments have also become platforms for their agenda. And unfortunately, their strategies seem to be working.
Read more here Approval, pricing, distribution — 5 questions India faces before rolling out Covid vaccine
The process of getting a Covid-19 vaccine out in India has been boosted after three manufacturers — Pfizer, Serum Institute of India and Bharat Biotech — applied for emergency use authorisation. Since its inception in August, the National Expert Group on Vaccine Administration for Covid (NEGVAC), which is providing guidance on priority groups and other things, has met at least nine times.
However, critical questions about rollout remain unanswered, including funding options, distribution of vaccines especially to remote areas, and the exact powers of regulatory bodies.
Read more here No law for bio emergencies, no strategy for next pandemic – India must learn from Covid
Coronavirus vaccines are here, but delivering them to billions of people is the next big challenge
After the effort put into developing and testing Covid-19 vaccines, another herculean task lies ahead: the logistics of vaccine rollout. For starters, this is the biggest vaccine supply chain challenge ever. But the challenges are not entirely new. The distribution of the Ebola vaccine relied on setting up ultra-cold chains in remote parts of the world. By bundling the knowledge and experience of the public and private sectors and humanitarian organisations, the vital supply chain for Covid vaccines can be successful.
Some vaccines, such as the mRNA vaccines that Pfizer and Moderna have developed, are what are known as “labile”. That is, they degrade each time they are moved and can eventually become inactive. A solution to this problem is relocating production facilities nearer to those who need to be immunised.
Read more here